Diligence memo · auto-generated · as of July 2, 2026
Atlas Oncology Holdings Inc.
Atlas Oncology Holdings Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Atlas Oncology Holdings Inc. operates in Pharma, based in NASHVILLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Atlas Oncology Holdings Inc. has raised $23M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $23M on 2026-02-10.
Most recent recorded round closed around 2026-02-10.
Valuation (modeled)modeled
Provath models Atlas Oncology Holdings Inc. at approximately $85M (range $48M–$112M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.88× the median modeled value of Series B Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era. Within the normal band (88% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 77% of Pharma peers (310 compared).
Modeled value ranks above 65% of those peers.
Closest niche peers: Juvena Therapeutics, Inc., Alessa Therapeutics, Inc., Amani Therapeutics, Inc., Shenandoah Therapeutics Inc., TwoStep Therapeutics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.